Why the study?
Does ischemia-modified albumin (IMA) predict cardiac outcomes in patients with potential cardiac ischemia?
Does ischemia-modified albumin (IMA) predict cardiac outcomes in patients with potential cardiac ischemia?
Answers are grounded in this paper and cite their sources.
Ischemia-modified albumin (IMA) is a poor predictor of cardiac outcomes in patients with suspected acute coronary syndromes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Giuseppe Lippi (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: